Trial Profile
Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Prasterone (Primary)
- Indications Dyspareunia
- Focus Therapeutic Use
- 08 Jun 2022 Status changed from recruiting to completed.
- 29 Aug 2018 Status changed from not yet recruiting to recruiting.
- 03 Jul 2018 New trial record